Robert Keith Woods's most recent trade in Tscan Therapeutics Inc was a trade of 67,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tscan Therapeutics Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | |
| Neurogene Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 12,050 | 12,050 | - | - | Non-Qualified Stock Option (right to buy) | |
| X4 Pharmaceuticals Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 1,500 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Robert Keith Woods | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 110,067 | 110,067 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Robert Keith Woods | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 500,000 | 600,000 (2%) | 1% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Robert Keith Woods | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 7,700 | 7,700 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Robert Keith Woods | Director | 13 Jun 2024 | 23,944 | 23,944 | - | - | Stock Option (Right to Buy) | ||
| Tscan Therapeutics Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 47,500 | 47,500 | - | - | Stock Option (Right to Buy) | |
| X4 Pharmaceuticals Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 135,000 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 15,400 | 15,400 | - | - | Stock Option (Right to Buy) | |
| Tscan Therapeutics Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) |